文献速递前列腺增生与排尿功能障碍

TAS-303治疗女性压力性尿失禁的疗效与安全性:一项2期随机双盲安慰剂对照试验

Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
PubMed 文献 · J Urol · 2024-07-09

这项2期随机双盲安慰剂对照试验将231例有压力性尿失禁(SUI)症状的日本女性分为TAS-303 18mg每日一次组(n=116)或安慰剂组(n=115),治疗12周。主要终点为符合方案集24小时平均SUI发作频率(SUIEF)自基线至第12周的变化百分比,TAS-303组为-57.7%,安慰剂组为-46.9%,组间最小二乘均值差为-10.8%(P=0.036)。TAS-303所有不良事件均为轻中度,无严重不良事件。

要点

  • TAS-303 18mg每日一次治疗12周,SUIEF较基线降低57.7%,优于安慰剂的46.9%(P=0.036)。
  • 基线每日SUI发作≥2次的患者中,组间SUIEF改善差异更明显。
  • TAS-303所有不良事件均为轻中度,无严重不良事件或导致停药的不良事件。

核心结论

  • 每日一次TAS-303 18mg对日本女性SUI的疗效优于安慰剂,且安全性良好。

研究设计与样本

  • 双盲、安慰剂对照的2期研究,将231例有SUI症状的女性随机分配至TAS-303 18mg每日一次口服组(n=116)或安慰剂组(n=115),治疗12周。

主要发现

  • 符合方案集中,第12周TAS-303组24小时平均SUIEF自基线变化的最小二乘均值为-57.7%,安慰剂组为-46.9%,组间最小二乘均值差为-10.8%(P=0.036)。
  • 全分析集中,第12周TAS-303在改善失禁发作频率、失禁量和健康相关生活质量方面显示一定证据,但未达统计学显著。
  • 基线每日SUI发作≥2次的患者中,组间SUIEF改善差异更明确。
  • TAS-303所有不良事件均为轻中度,无严重不良事件、无导致停药的不良事件,也无神经系统或胃肠道相关(如恶心或呕吐)的药物不良反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to evaluate the therapeutic efficacy and safety of TAS-303, a highly selective noradrenaline reuptake inhibitor, in Japanese women with stress urinary incontinence (SUI). MATERIALS AND METHODS: A double-blind, placebo-controlled, phase 2 study randomized women with SUI symptoms to once-daily oral administration of TAS-303 18 mg or placebo for 12 weeks. The primary endpoint was percent change from baseline to Week 12 in mean SUI episode frequency per 24 hours (SUIEF) in the per-protocol set. The secondary endpoints were the proportion of patients with ≥ 50% reduction in mean SUIEF, incontinence episode frequency, incontinence amount, health-related quality of life, and safety in the full analysis set. RESULTS: In total, 231 patients were randomized to TAS-303 (n = 116) or placebo (n = 115). At Week 12, TAS-303 had superior efficacy to placebo, with a least squares mean percent change in mean SUIEF of -57.7% vs -46.9%, respectively, in the per-protocol set (least squares mean difference -10.8%; P = .036). TAS-303 showed some evidence of improved incontinence episode frequency, incontinence amount, and health-related quality of life (although not statistically significant) at Week 12 vs placebo in the full analysis set. The between-group difference in SUIEF improvement was more clearly confirmed in patients with ≥ 2 SUI episodes daily at baseline. All adverse events (AEs) with TAS-303 were mild or moderate; there were no serious AEs, AEs leading to discontinuation, or nervous system- or gastrointestinal-related (eg, nausea or vomiting) adverse drug reactions. CONCLUSIONS: Once-daily TAS-303 18 mg showed superior efficacy to placebo for the treatment of SUI in Japanese women, with an adequate safety profile. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04512053; Japan Registry of Clinical Trials: jRCT2080225307 (JapicCTI-205403 before site integration).

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Takahashi S, Kato K, Yokoyama O, et al. Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial. J Urol. 2024. PMID: 38979756. doi:10.1097/JU.0000000000004024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。